Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS3681 in mCRPC
NCT02566772Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Mar 2016
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of TAS3681 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Taiho Oncology. Primary endpoints: Dose-Limiting Toxicities at 1 month, Adverse Events at 6 months and 1 more. Started Mar 2016; status: completed.
02
Drugs
TAS3681
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02566772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566772.